Immune response against SARS-CoV-2 vaccination

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028174

Enrollment

Registered

2022-02-25

Start date

2022-02-27

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: Blood samples will be collected from volunteers who plan to get vaccinated with COVID-19 mRNA vaccines before and at weekly intervals after the vaccination.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: healthy who can give informed consent

Exclusion criteria

Exclusion criteria: Volunteers who suffer from chronic or acute direct (infections, autoimmunity, tumors, congenital) or indirect (drug induced) immune defects

Design outcomes

Primary

Measure	Time frame
The overall goal of the study is a detailed longitudinal characterisation of the B- and T-Zell response in peripheral blood after SARS-CoV-2 mRNA vaccination. The study aims to provide fundamental molecular, cellular and functional insights in the development and quality of B- and T-cell responses on single-cell level.	—

Secondary

Measure	Time frame
same as primary outcome	—

Countries

Germany

Contacts

Public ContactHedda Wardemann

DKFZ

h.wardemann@dkfz.de06221421270

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026